ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics ...

Orion Corporation ("Orion"), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today ...

ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody ...

Theradaptive, a Maryland-based, privately held, clinical-stage biologics company, today announced the initiation of patient dosing in Maryland for the ongoing OASIS Phase I/II clinical trial assessing ...

For the seventh consecutive year, the Black Book Market Research User Survey has ranked Orchard Software as the top laboratory information system (LIS) vendor. In the 2025 survey, Orchard took the top ...

The ADC is due to start testing in humans this year. Earlier deals included a collaboration with Invenra on ‘multispecific’ antibodies that can target more than one target simultaneously ...

The Business Launcher simplifies the entrepreneurial journey by offering a personalized, end-to-end solution that translates users' skills and experiences into viable business ventures.

After hours: 7:30:02 pm GMT-5 ...

Our CEO Gilmore O’Neill at the 43rd Annual J.P. Morgan Healthcare Conference highlighting new in vivo preclinical proof of concept data, anticipated 2025 key milestones, and our three-year ...